Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

16-20 of 52 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

A Phase 1/2 Study of VX-121 in Subjects With Cystic Fibrosis and in Subjects without Cystic Fibrosis (VX17-121-001)

The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis.

Phase I/II
  • Trial Reference Number

    111537

  • Mutation

    One copy of F508del

  • Age

    18+

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

Gastro-oesphageal reflux in patients with cystic fibrosis and its effect on lung function

Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and /or surgical procedures. The aim of this observational study is to investigate if GORD affects the lung function. The study will assess mircobiology and presence of markers of reflux aspiration. These are substances that are found in the gastrointrestinal tract and that , if detected in sputum, support the presence of stomach contents in the lungs. In addition factors that may influence GORD such as antacids tablets and enteral feeding ( via a tube into the stomach) will be evaluated. GORD will be measured by using special probes that assess the function of the oesophagus, PH (acidity) and presence of gastic contents within the gullet. The participants will provide measures of lung function, clinical details, blood, and sputum samples as well as complete symptoms questionnaires

Read more
  • Trial Reference Number

    105287

  • Age

    18+

  • Length of participation

    24 hours

  • Trial status

    Closed - follow up complete

  • Therapeutic category

    Other

Gut - CF

Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a week. A final group of patients will be asked to complete the form before and after certain treatments so we can assess how bowel symptoms change over a course of treatment. Once we are happy that the CF-BS questionnaire captures symptoms that affect CF patients it will be distributed to the rest of the patients at the Manchester Adult CF Centre. This will allow us to identify the number of patients with bowel symptoms and allow us to better treat them

Read more
  • Trial Reference Number

    106002

  • Age

    18+

  • Length of participation

    1 week

  • Trial status

    Closed - follow up complete

  • Therapeutic category

    Other

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy (VX17-445-105)

This study will evaluate the long-term safety and tolerability of VX-445 in triple combination withT ezacaftor (TEZ) and Ivacaftor (IVA) in subjects with cystic fibrosis who are homozygous or heterozygous for the F508del mutation..

Phase III
  • Trial Reference Number

    109563

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

GLPG2737-CL-105 Assessment of multiple oral doses of GLPG2451/GLPG2222

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated anion channel expressed primarily at the apical plasma membrane of secretory epithelia. Over 2,000 mutations in the CFTR gene have been identified, which are grouped into 6 classes (class I-VI). The F508del mutation is by far the most common CFTR mutation globally, especially in the Caucasian population. Approximately 80 to 90% of CF patients in the United States and Europe have at least one copy of this mutation on one allele, with almost half of them being F508del homozygous (i.e., the mutation is present on both alleles). The F508del mutation impairs CFTR folding, stability at the endoplasmic reticulum and plasma membrane, and chloride gating. Thus, the F508del mutation results in very little to no CFTR protein in the apical membrane. CFTR dysfunction results in increased chloride concentration in sweat and viscous secretions that are difficult to clear, affecting most exocrine glands, notably the pancreas, intestine, liver, and bile duct. However, most morbidity and mortality results from dehydration of the airway surface liquid and impaired airway mucociliary clearance, which leads to cycles of bacterial infection, chronic inflammation, bronchiectasis and progressive decline in pulmonary function. There is a high unmet medical need for subjects with CF, especially for subjects that are either homozygous or heterozygous for the F508del mutation (with a potentiator non-responsive mutation on the second allele). GLPG2451, GLPG2222 and GLPG2737 are in clinical development for the oral treatment of CF, and represent the components of a potentiator/correctors triple combination therapy targeting the F508del CF subject population.

Read more Phase I
  • Trial Reference Number

    104923

  • Age

    18+

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

16-20 of 52 results for all trials